Year | All antipsychotics | LAI risperidone | All LAI SGAs | LAI paliperidone | LAI FGAs | SGA oral | FGA oral | LAI SGA expenditures as % of total antipsychotic expenditures per Veteran |
---|---|---|---|---|---|---|---|---|
2007 | $122,170,267 | $12,914,274^ | $12,914,274^ | $0 | $371,238 | $76,078,149 | $32,806,605 | 10.6^ |
2008 | $128,140,495 | $15,085,187^ | $15,085,187^,# | $0 | $348,750 | $82,396,607 | $30,309,950 | 11.8^ |
2009 | $115,066,407 | $16,832,583 | $16,881,109^ | $48,526^ | $358,936 | $86,271,426 | $11,554,935 | 14.7^,# |
2010 | $116,571,834 | $16,878,621 | 18,142,921^,# | $1,263,172^,# | $370,713 | $91,405,234 | $6,652,966 | 15.6^,# |
2011* | $117,202,917 | $16,062,864 | $20,802,052 | $4,737,495 | $805,706 | $90,968,967 | $4,626,193 | 17.8 |
2012 | $96,742,862 | $14,562,180 | $22,761,616^ | $8,192,594^ | $1,017,493 | $68,812,359 | $4,151,395 | 23.5^ |
2013 | $76,508,388 | $12,757,391 | $23,476,864^ | $10,544,810^ | $846,056 | $48,876,894 | $3,308,575 | 30.7^,# |
2014 | $70,692,177 | $12,378,899 | $26,402,932^,# | $13,341,523^,# | $919,701 | $40,500,060 | $2,869,484 | 37.4^ |
2015 | $73,982,381 | $11,135,327^ | $30,164,815^,# | $17,156,228^ | $869,519 | $40,245,255 | $2,702,792 | 40.8^,# |
Change | ($48,187,886) | ($1,778,947) | $17,250,541 | $17,156,228 | $498,281 | ($35,832,894) | ($30,103,814) | 30.2% |
Percent change | − 39.4% | − 13.8% | 133.6% | –- | 134.2% | − 47.1% | − 91.8% | 285.7% |